NEW YORK, Feb. 25 (GenomeWeb News) - Ingenium Pharmaceuticals will develop animal models with defined gene mutations for Gr nenthal, the German companies said today.
Ingenium, of Munich, will utilize its Ingenotyping technology, which enables it to create in four months a series of mammalian models carrying genetic alterations in any target gene of interest, according to the company.
Gr nenthal, based in Aachen, plans to use the animal models resulting from the collaboration to validate targets for the treatment of pain.